Clinical observation of Endostar combined with chemoradiotherapy for patients with locally advanced esophageal carcinoma

Abstract

Objective To investigate the short-term effect of recombinant human endostatin (Endostar) combined with chemoradiotherapy(CRT) on patients with locally advanced esophageal squamous cell carcinoma(ESCC).Methods Twenty-eight patients were treated with Endostar plus CRT(group E)and 27 patients were treated with CRT(group C).All the patients received three-dimensional conformal radiotherapy of 60-66 Gy and concurrent chemotherapy of 5 fluorouracil and cisplatin.Endostar was administered at a dose level of 7.5 mg/(m2 · d) on the day of CRT(d 1-14)and 2 cycles were given.The response rate (RR),progression free survival(PFS),overall survival rate(OS) and side effects were assessed after treatment.The serum VEGF(S-VEGF) levels were measured before and after the treatment in both groups.Results The RR in group E was 89.0％ and 74.1％ in group C(P =0.226).The 1,2,3OS rate was 71.9％,50.0％,34.3％ and 52.0％,33.3％,20.0％ (P =0.046),PFS were 15 months and 8 months for group E and group C respectively(P =0.0015).There were no side effects associated with Endostar.There were significant differences in S-VEGF level after treatment (P =0.009) between the two groups.Conclusions The effect of Endostar combined with chemoradiotherapy on patients with locally advanced esophageal squamous cell carcinoma is remarkable,it can reduce the S-VEGF level,and has good tolerance. Key words: Esophageal carcinoma; Endostar; Concurrent chemoradiotherapy; Serum vascular endothelial growth factor